 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| Stimplate (romiplostim biosimilar) / Generium
Trial completion: Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - Jun 21, 2024
P3, N=160, Completed, Sponsor: AO GENERIUM
Enrolling by invitation --> Completed
- ||||| Stimplate (romiplostim biosimilar) / Generium
Trial completion: Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (clinicaltrials.gov) - Mar 6, 2024
P3, N=160, Completed, Sponsor: AO GENERIUM
Enrolling by invitation --> Completed Recruiting --> Completed
- ||| Stimplate (romiplostim biosimilar) / Generium
Trial primary completion date: Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - Mar 6, 2024
P3, N=160, Enrolling by invitation, Sponsor: AO GENERIUM
Recruiting --> Completed Trial primary completion date: Nov 2023 --> Apr 2024
- ||| Stimplate (romiplostim biosimilar) / Generium
Trial completion date, Trial primary completion date: Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - Mar 1, 2023
P3, N=160, Enrolling by invitation, Sponsor: AO GENERIUM
Trial primary completion date: Nov 2023 --> Apr 2024 Trial completion date: Aug 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Nov 2023
- ||| Stimplate (romiplostim biosimilar) / Generium
Trial completion date, Trial primary completion date: Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (clinicaltrials.gov) - Feb 23, 2023
P3, N=160, Recruiting, Sponsor: AO GENERIUM
Trial completion date: Aug 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Nov 2023 Trial completion date: Feb 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Nov 2023
- |||||||| Stimplate (romiplostim biosimilar) / Generium
New P3 trial: Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - Aug 8, 2022
P3, N=160, Enrolling by invitation, Sponsor: AO GENERIUM
- |||||||| Stimplate (romiplostim biosimilar) / Generium
New P3 trial: Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (clinicaltrials.gov) - Feb 2, 2022
P3, N=160, Recruiting, Sponsor: AO GENERIUM